A Breakthrough In The Early Detection Of Lung Cancer

The first commercially available biomarker to detect DNA changes (does not require capturing a cancer cell) — helps accelerate cancer detection

Useful complement to CT, bronchoscopy, endoscopy, and x-ray methods — adds value to your diagnosis

A convenient test for your high-risk cancer candidates — simple, painless, noninvasive and radiation free

Information And Ordering

Toll free: 1-888-629-8779
E-mail: info@LungSign.com
Web site: www.LungSign.com

A physician’s requisition is required. You may wish to advise your patient that this test is currently NOT covered by insurance (payment is $175).

References

   MMHC Lung Cancer Site.

LungSign™ and Early detection, better outcomes™ are trademarks of Perceptronix Medical, Inc.

©Copyright 2008 Perceptronix Medical, Inc. All rights reserved. October 2008 PB-17–1.2
Lung Cancer – The Leading Cause Of Cancer Death In Canada

No. 1 In Morbidity – The Highest Incidence In Canada

According to the World Health Organization, lung cancer accounts for 1.3 million new cases worldwide every year. Lung cancer mortality exceeds the combined total for the next 3 most lethal cancers: breast, colorectal and prostate. It is also the second most common form of cancer in Canada.

Cancer Occurrence In Canada

<table>
<thead>
<tr>
<th>Rank</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Prostate</td>
</tr>
<tr>
<td>2</td>
<td>Lung</td>
</tr>
<tr>
<td>3</td>
<td>Breast</td>
</tr>
<tr>
<td>4</td>
<td>Colorectal</td>
</tr>
<tr>
<td>5</td>
<td>Non-Hodgkin’s</td>
</tr>
<tr>
<td>6</td>
<td>Bladder</td>
</tr>
<tr>
<td>7</td>
<td>Melanoma</td>
</tr>
<tr>
<td>8</td>
<td>Leukemia</td>
</tr>
<tr>
<td>9</td>
<td>Kidney</td>
</tr>
<tr>
<td>10</td>
<td>Thyroid</td>
</tr>
</tbody>
</table>

Despite efforts to develop detection technologies and new treatments, little progress has been made to reduce lung cancer mortality over the last 30 years.

Long-Term Survival Is Grim

The prognosis for patients with lung cancer is poor. The 5-year survival rate is less than 15%, a figure that plummets to 2% once the cancer has metastasized. In contrast, patients with lung cancer detected at stage I (localized lesion < 3 cm in diameter) have an estimated 88% 10-year survival rate.

Currently, only 16% of lung cancers are detected while still confined to the primary site.

Survival Advantage Of Early Detection

Early detection is essential to the overall improvement of lung cancer outcomes.
LungSign™—
A Breakthrough In Early Detection Of The Most Deadly Form Of Cancer

Opening An Exciting New Window Into Earlier Lung Cancer Detection

LungSign™ is the first test that offers a safe, painless and convenient method of assessing a patient’s risk of lung cancer. The test provides biological evidence associated with lung malignancy.

CT Scans Only Tell Part Of The Story

Useful Complement To CT, Bronchoscopy, Endoscopy And X-Ray Methods

As the resolution of CT scanners has increased, so has the fraction of patients found to have suspicious nodules. This points to a specificity limitation with CT, leading to a high rate of follow-up on false-positive results. In addition, many physicians worry about the effect of CT radiation exposure, especially on population groups for whom radiation should be limited. By updating a patient’s pretest risk of lung cancer, LungSign™ may eliminate a significant number of unnecessary CTs.

Highly Correlated With Lung Cancer, Even In The Presymptomatic Early Stage

With LungSign™, finding an actual cancer cell is not necessary to detect lung cancer. In the presence of cancerous lesions, normal cells undergo subtle malignancy-associated changes. Based on an innovative marker for malignancy, LungSign™ is designed to detect cancer in stage one or even earlier. LungSign™ is not a diagnostic test. It utilizes innovative DNA cytometry technology to assess risk. It is the only commercial test approved to detect DNA ploidy in normal appearing cells and help accelerate cancer diagnosis.

Engineered by researchers at the British Columbia Cancer Agency, the potential of LungSign™ has been established through a multicentered validation trial. The trial demonstrated that fully automated DNA analysis of sputum cells using LungSign™ detects stage I cancer regardless of location or type of lung cancer (Squamous or adenocarcinoma, central or peripheral).

CT Scans Only Tell Part Of The Story
As the resolution of CT scanners has increased, so has the fraction of patients found to have suspicious nodules. This points to a specificity limitation with CT, leading to a high rate of follow-up on false-positive results. In addition, many physicians worry about the effect of CT radiation exposure, especially on population groups for whom radiation should be limited. By updating a patient’s pretest risk of lung cancer, LungSign™ may eliminate a significant number of unnecessary CTs.

Useful Complement To CT, Bronchoscopy, Endoscopy And X-Ray Methods

There is demand for a means to select individuals for CT lung cancer screening from very high-risk patient groups. LungSign™ provides a good solution, because it is noninvasive, inexpensive and radiation free, and the results deliver biologically relevant new information.

LungSign™ detects early signs of cancer not readily detectable with CT technology or other diagnostic tools.
LungSign™
A Safe, Painless And Simple Test For High-Risk Lung Cancer Candidates

Appropriate Patient Groups
High-risk candidates:

- over 50 years old
- significant exposure to cigarette smoke (more than 1 pack per day for over 20 years) or industrial carcinogens (e.g. asbestos, radon)
- presenting symptoms such as persistent cough or shortness of breath

In addition:

- patients suspicious for lung cancer or those being considered for CT screening
- post-CT patients seeking to assess the potential of malignancy
- patients for whom radiation from CT or x-ray should be limited (e.g. women at risk for breast cancer, female smokers or lung cancer survivors)
- lung cancer survivors monitoring for recurrence
- patients in need of motivation-related smoking cessation tools

Taking the LungSign™ test causes very little physical discomfort. Almost anyone can take the LungSign™ test, with the following exceptions:

- patients who have had an asthma attack or COPD (chronic obstructive pulmonary disease) exacerbations in the last 5 days
- patients with flu-like symptoms such as fever or chills

The LungSign™ kit also should not be used by those suffering from pneumothorax. The use of the kit requires an increased effort in exhalation that may not be tolerated by those with cardiovascular difficulties or recent surgery. The LungSign™ kit should only be used by patients able to tolerate the procedure.

Analysis And Reporting
Once collected, using the LungSign™ sputum collection kit, samples are sent to the Perceptronix Laboratory for analysis. LungSign™ reports are sent only to the patient’s physician.

Interpreting LungSign™
The LungSign™ kit provides important information about a patient’s risk of lung cancer. Likelihood multipliers assigned by LungSign™ update a patient’s risk of harbouring the disease. Thus, results should be interpreted in the context of a patient’s medical history and background risk for lung cancer. Although not a diagnostic test, the existence of a likelihood predictor such as LungSign™ potentially may have significant value in the fight against lung cancer.

Perceptronix Medical, Inc.
The LungSign™ kit was developed by Perceptronix Medical, Inc. The goal of Perceptronix is to create products and services that support the early diagnosis of lung cancer for better patient outcomes.

Perceptronix believes that early diagnosis is the key to improving outcomes for lung cancer patients.

www.LungSign.com